Abstract
The MICs of fluconazole for strains of Candida species and the levels of fluconazole in serum were determined at day 0 and day 14 for 23 human immunodeficiency virus-infected patients with oral candidiasis who were treated orally with 100 mg of fluconazole per day for 14 days. Among the 23 patients, 11 (48%) were not clinically cured and had persistent isolation of Candidiasis albicans (n = 10) and/or presence of non-C. albicans (n = 6). Clinical response could be predicted by the susceptibility of the strain to fluconazole determined at day 0. All 12 patients who were cured were infected with a strain for which the MIC was < 0.78 mg/liter. All four patients who were infected with a strain for which the MIC was > 3.12 mg/liter experienced clinical failure. These data suggest that a C. albicans strain could be defined as being susceptible when the MIC of fluconazole is < 0.78 mg/liter and as being resistant when the MIC is > 3.12 mg/liter.
Full Text
The Full Text of this article is available as a PDF (177.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baily G. G., Perry F. M., Denning D. W., Mandal B. K. Fluconazole-resistant candidosis in an HIV cohort. AIDS. 1994 Jun;8(6):787–792. doi: 10.1097/00002030-199406000-00010. [DOI] [PubMed] [Google Scholar]
- Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
- Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Franker C. K., Lucartorto F. M., Johnson B. S., Jacobson J. J. Characterization of the mycoflora from oral mucosal surfaces of some HIV-infected patients. Oral Surg Oral Med Oral Pathol. 1990 Jun;69(6):683–687. doi: 10.1016/0030-4220(90)90348-v. [DOI] [PubMed] [Google Scholar]
- Gazzard B. G., Smith D. Oral candidosis in HIV-infected patients. Br J Clin Pract Suppl. 1990 Sep;71:103–108. [PubMed] [Google Scholar]
- Newman S. L., Flanigan T. P., Fisher A., Rinaldi M. G., Stein M., Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):684–686. doi: 10.1093/clinids/19.4.684. [DOI] [PubMed] [Google Scholar]
- Powderly W. G. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS. 1992 Jun;6(6):604–605. [PubMed] [Google Scholar]
- Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994 Sep;32(9):2092–2098. doi: 10.1128/jcm.32.9.2092-2098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]